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Pirfenidone decreases 
mesothelioma cell proliferation and 
migration via inhibition of ERK and 
AKT and regulates mesothelioma 
tumor microenvironment in vivo
Chang Li1,2, Veronika Rezov1, Emmi Joensuu1, Ville Vartiainen  1,4, Mikko Rönty3, Miao Yin1, 
Marjukka Myllärniemi4 & Katri Koli1
Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent 
extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the 
ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as mesothelioma 
tumor microenvironment was evaluated. Pirfenidone is an anti-fibrotic drug used in the treatment of 
idiopathic pulmonary fibrosis and has also anti-proliferative activities. Mesothelioma cell proliferation 
was decreased by pirfenidone alone or in combination with cisplatin. Pirfenidone also decreased 
significantly Transwell migration/invasion and 3D collagen invasion. This was associated with increased 
BMP pathway activity, decreased GREM1 expression and downregulation of MAPK/ERK and AKT/mTOR 
signaling. The canonical Smad-mediated TGF-β signaling was not affected by pirfenidone. However, 
pirfenidone blocked TGF-β induced upregulation of ERK and AKT pathways. Treatment of mice 
harboring mesothelioma xenografts with pirfenidone alone did not reduce tumor proliferation in vivo. 
However, pirfenidone modified the tumor microenvironment by reducing the expression of extracellular 
matrix associated genes. In addition, GREM1 expression was downregulated by pirfenidone in vivo. 
By reducing two major upregulated pathways in mesothelioma and by targeting tumor cells and the 
microenvironment pirfenidone may present a novel anti-fibrotic and anti-cancer adjuvant therapy for 
mesothelioma.
Malignant mesothelioma is an asbestos exposure-related aggressive cancer, which most often occurs in the 
pleura1,2. The prognosis is poor, survival is usually only ~10 months from diagnosis. Mesothelioma originates 
from serosal mesothelial cells with three histological subtypes. The epithelioid mesothelioma is the most common 
type with prominent papillo-tubular structures, the sarcomatoid mesothelioma is characterized by spindled cells 
mimicking fibrosarcoma and the biphasic mesothelioma displays both epithelioid and sarcomatoid histology. 
Sarcomatoid mesothelioma is the most aggressive type and has the worst prognosis3. Mesothelioma shows pro-
gressive local growth and aggressive invasion into the neighboring tissue. Tumor cells can also travel to nearby 
lymph nodes, but the tendency to distant metastasis is usually low. Currently, mesothelioma remains an incurable 
disease with limited treatment options4,5.
The genetic and molecular profiling of mesothelioma has led to the identification of pathways involved in driv-
ing mesothelioma growth and invasion. Mesothelioma is characterized by loss of tumor suppressor genes rather 
than oncogene activation. The most commonly mutated genes are CDKN2A/ARF, BAP1 and NF26. Analyses 
of alterations in signaling pathway activities have identified consistent upregulation of the PI3K/AKT/mTOR 
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pathway7. In addition, activation of epidermal growth factor (EGF), platelet derived growth factor (PDGF) and 
hepatocyte growth factor (HGF) pathway signaling as well as the angiogenic vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) pathways have been reported8,9. We and others have linked trans-
forming growth factor (TGF)-β pathway activation to mesothelioma invasive growth8,10,11. The characterization 
of these re-expressed developmental pathways, which drive proliferation and give rise to migratory and invasive 
cancer cell phenotypes, may lead to new target identification.
We have recently identified the BMP inhibitor protein gremlin-1 to be upregulated in mesothelioma12. 
Gremlin-1 drives a mesenchymal and chemoresistant phenotype in mesothelioma cells. Gremlin-1 expression 
is also associated with invasion and metastasis as well as tumor vascularization in an in vivo mouse model11. 
Downregulation of BMP pathway activity is associated with increased TGF-β pathway activity, resulting in imbal-
ance of growth factor activities. Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized 
by accumulation of fibroblasts/myofibroblasts, excessive matrix production and altered TGF-β/BMP signaling 
balance13,14. We have shown that restoration of the impaired BMP signaling activity, by administration of BMP-7 
or using the small molecule drug tilorone, reduces fibrosis in experimental mouse models15,16. Fibrotic altera-
tions in the tumor microenvironment can promote tumor proliferation and invasive behavior17. Pirfenidone is 
an anti-fibrotic drug used in the treatment of IPF patients13. Although the mechanisms of action are not fully 
characterized, pirfenidone is thought to act by reducing TGF-β-mediating signaling in IPF18. We hypothesized 
that by altering tumorigenic signaling pathways in mesothelioma cells and by modulation of the tumor stroma 
pirfenidone could reduce mesothelioma cell growth and invasion.
Results
Pirfenidone reduces mesothelioma cell proliferation, migration and 3D invasive growth. First, 
we analyzed the effects of pirfenidone on mesothelioma cell proliferation. JL-1, H2052 and JP5 human mesotheli-
oma cells as well as AB12 mouse mesothelioma cells showed significantly reduced proliferation when treated with 
pirfenidone for 48 hours (Fig. 1A). Pirfenidone concentration of 750 μg/ml reduced proliferation in H2052 cells 
Figure 1. Pirfenidone inhibits mesothelioma cell proliferation. WST-1 assay was used to analyze cell 
proliferation. (A) Human (JL-1, H2052 and JP5) and mouse (AB12) mesothelioma cells were treated with 
increasing concentrations of pirfenidone (PFD, 0–750 μg/ml) for 2 days. The results are expressed relative to the 
proliferation in control treated cells, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (B) JL-1 
and H2052 cells were treated with increasing concentrations of cisplatin (0–30 μM) for 2 days. The results are 
expressed relative to the proliferation in control treated cells, which was set to 1. A representative experiment 
is shown. For combined treatment studies with pirfenidone a concentration of 10 μM cisplatin was chosen. (C) 
JL-1 and H2052 cells were treated with cisplatin and/or pirfenidone (PFD, 0–750 μg/ml) for 2 days. The results 
are expressed relative to the proliferation in control treated cells, which was set to 1. The error bars represent SD 
(n = 3). *p < 0.05.
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to ~50% of control level (non-treated cells), while in the other cells ~70% reduction was observed. A concentra-
tion of 10 μM cisplatin reduced proliferation ~20% in JL-1 and H2052 cells (Fig. 1B) and was chosen for further 
experiments combining cisplatin with pirfenidone. Cisplatin had at least an additive effect in the reduction of 
JL-1 and H2052 mesothelioma cell proliferation when combined with pirfenidone (Fig. 1C). Cisplatin and pem-
etrexed combination presents the standard chemotherapy regiment in the treatment of mesothelioma patients19. 
We tested also pemetrexed in a similar proliferation assay, but did not find any additional effect when combined 
with pirfenidone (data not shown).
Transwell migration assay was used to assess the effect of pirfenidone on mesothelioma cell migration. JL-1 
and H2052 cell migration/invasion through collagen 1 coated inserts was reduced significantly in a concentration 
dependent manner (Fig. 2A,B). H2052 cells are able to invade and sprout through the surrounding matrix when 
embedded into 3D Matrigel11. Pirfenidone reduced sprouting of H2052 cells in 3D Matrigel (Fig. 2C). Invasive 
growth and sprouting of JL-1 cells in 3D collagen matrix was also noticeably reduced by pirfenidone treatment 
(Fig. 2D and Supplementary Fig. 2). These results suggest that pirfenidone is a novel inhibitor of mesothelioma 
cell proliferation and migration.
BMP signaling activity is increased in pirfenidone treated mesothelioma cells. We have previ-
ously linked high gremlin-1 expression and aberrant TGF-β/BMP signaling activity to mesothelioma invasive 
growth11. Gremlin-1 mediated reduction in BMP-pathway activity and increased TGF-β pathway activity drive 
invasive growth of mesothelioma cells11. Here, we observed a concentration-dependent increase in BMP-pathway 
activity in pirfenidone treated JL-1 and H2052 cells (Fig. 3A). This was associated with increased expression of 
the BMP-pathway target gene ID1 (Fig. 3B). Interestingly, the expression of GREM1 was significantly reduced 
by pirfenidone in the two different mesothelioma cell lines, suggesting a mechanism by which pirfenidone can 
rescue BMP-pathway activity (Fig. 3B). TGF-β-pathway reporter activity (Smad3 dependent, see Methods) was 
not reduced by pirfenidone with or without TGF-β treatment (Fig. 3C). TGF-β induced phosphorylation of 
Smad2 was not reduced either in JL-1 or H2052 cells (Fig. 3D). Furthermore, no significant changes were noted 
in TGFB1 mRNA expression levels (Fig. 3E). In contrast to previous observations, these results suggest that at 
least in mesothelioma cells, the anti-tumor and anti-fibrotic activity mediated by pirfenidone is independent of 
the canonical TGF-β signaling.
MAPK/ERK and AKT pathway activities are reduced by pirfenidone. To investigate cellular sign-
aling pathways affected by pirfenidone treatment, we analyzed alterations in phospho-kinase levels in JL-1 and 
H2052 cells using a commercial array (see Methods). The assay was repeated twice to screen for signaling dif-
ferences. Phospho-ERK1/2 (P-ERK1/2) and P-CREB were the only phospho-proteins consistently reduced by 
pirfenidone treatment in both cell lines (Fig. 4A). P-ERK1/2 levels were also analyzed by ELISA and observed to 
be decreased by pirfenidone, while P-p38 and P-JNK1/2 levels were not altered (Fig. 4B). Since TGF-β is known 
to regulate MAPK-pathways20 we analyzed P-ERK1/2 levels also in TGF-β stimulated cells by ELISA. TGF-β 
was found to increase P-ERK1/2 levels in H2052 cells (Fig. 3C). Pirfenidone reduced P-ERK1/2 in both TGF-β 
treated and non-treated cells. In agreement, immunoblotting analysis of P-ERK1/2 levels indicated significant 
concentration dependent reduction by pirfenidone in H2052 cells (Fig. 4D,E). Although pirfenidone did not 
reduce canonical Smad-mediated TGF-β signaling in mesothelioma cells, it was able to reduce TGF-β-mediated 
induction of ERK-pathway activation.
AKT-mediated signaling is often activated in mesothelioma and contributes to cell survival and proliferation7. 
It is also known to be regulated by TGF-β pathway activity21. The effect of pirfenidone on AKT and CREB pro-
teins was therefore analyzed using ELISA and Western blotting. P-CREB levels were decreased by pirfenidone 
and increased by forskolin (FSK) treatment used as a positive control for CREB activation (Fig. 5A). Total CREB 
levels were not altered by pirfenidone or forskolin in the ELISA assay (not shown). Western blotting indicated 
that P-AKT level was low in non-treated JL-1 cells and was increased by TGF-β treatment (Fig. 5B). Pirfenidone 
reduced P-AKT level in TGF-β treated cells. Notably, total AKT level was also decreased in both TGF-β treated 
and non-treated cells. A concomitant decrease in P-CREB levels was observed, consistent with the ELISA results 
(Fig. 5C). Pirfenidone induced decrease in P-CREB and AKT levels was concentration- and time-dependent 
(Fig. 5C,D). In JL-1 cells 1 hour treatment with pirfenidone was enough to reduce AKT level suggesting that 
protein degradation may mediate the effect of pirfenidone. Treatment of JL-1 and H2052 cells with the proteas-
ome inhibitor MG132 (10 μM) increased AKT protein levels in TGF-β treated and non-treated cells (Fig. 5E,F). 
In addition, MG132 rescued AKT levels in pirfenidone treated cells. P-CREB levels also increased in TGF-β 
treated and non-treated JL-1 cells, however, MG132 was only slightly able to rescue P-CREB levels in pirfenidone 
treated JL-1 or H2052 cells (Fig. 5E,F, Supplementary Fig. 3). Similar to what was found in TGF-β treated cells, 
pirfenidone decreased AKT levels also in the presence of PDGF-BB (data not shown). The results indicate that 
pirfenidone can decrease AKT and CREB pathways and that proteasome mediated degradation of AKT may play 
a functional role in mesothelioma cells.
Pirfenidone decreases p70S6K phosphorylation. Activation of the PI3K/AKT pathway leads to acti-
vation of mammalian target of rapamycin (mTOR), which initiates phosphorylation and activation of p70S6K 
(Fig. 6A). Pirfenidone treatment was found to decrease P-p70S6K levels in both JL-1 and H2052 cells (Fig. 6B,C). 
Taken together, our results indicate that pirfenidone targets multiple pathways (MAPK/ERK and AKT/mTOR) 
involved in mesothelioma cell survival and motility (Fig. 6A). Consistent with this observation, the effect of pir-
fenidone on mesothelioma cell proliferation was replicated by combining the AKT inhibitor (MK2206) and the 
MEK inhibitor (PD98059). Proliferation was decreased in an additive manner (Fig. 6D).
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Pirfenidone modulates mesothelioma tumor microenvironment. An in vivo study was performed 
using injection of JP5 mesothelioma cells subcutaneously as Matrigel plugs into nude mice (see Methods). In 
agreement with our previous studies all mice developed tumors as detected by luciferase signal11. Treatment 
with pirfenidone (200 mg/kg/day PO) was started one day after the injection of the tumor cells. Mice receiving 
pirfenidone showed a non-significant weight loss from day 12 onwards (Supplementary Fig. 4). No difference in 
tumor luciferase signal was detected between control (PBS) and pirfenidone treated mice during the experiment 
(n = 8, Fig. 7A,B). Mice were sacrificed at 2 months and the tumors stained with laminA + C antibody to iden-
tify cells of human origin. Lamin staining as well as tissue histology revealed an epithelioid pattern as expected 
Figure 2. Pirfenidone reduces mesothelioma cell migration and 3D invasive growth. (A) Invasive migration 
was analyzed using collagen 1 coated Transwell inserts. Control or pirfenidone (PFD) treated migrated cells 
were fixed, stained and imaged 16 hours after seeding. Representative images of crystal violet stained JL-1 cells 
are shown. (B) Invasive migration of JL-1 and H2052 cells 16 hours after seeding is shown. Graphs represent 
quantification of relative migration. The error bars represent SD (n = 3). *p < 0.05. (C) H2052 cells were 
embedded into 3D Matrigel matrix. Images of control and pirfenidone (PFD) treated cells from a representative 
experiment are shown. (D) Invasive growth of control or pirfenidone (PFD) treated JL-1 cells was analyzed 
in 3D collagen 1 matrix. Cells were followed up to 72 hours. Representative images are shown. Graph shows 
quantification as relative spheroid surface area. The error bars represent SD (n = 3). *p < 0.05.
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(Fig. 7C). Ki67 staining indicated no significant differences in proliferation between control and pirfenidone 
treated mice [percent Ki67 positive area (mean ± SD) was 12.1 ± 1.7 in control and 12.2 ± 2.1 in pirfenidone 
group, n = 8]. The results suggest that pirfenidone as a single agent at 200 mg/kg dose is not enough to reduce 
tumor cell proliferation.
To gain insight into pirfenidone induced alterations in gene expression, RNA sequencing of tumor tissue 
samples was performed (see Methods). Differentially expressed genes were mostly genes downregulated in pir-
fenidone treated tumors (101/127, Supplementary Table 1). Analysis of enriched Reactome pathways identified 
an extracellular matrix organization gene signature with over 30 genes downregulated by pirfenidone treatment 
(Fig. 7D). This gene signature included collagen genes (e.g. COL1A1, COL1A2, COL3A1), collagen modify-
ing genes (e.g. LOXL3, P3H3, P4HA3), other matrix protein and glycoprotein genes (e.g. FBN1, TNC, THBS1, 
Figure 3. Increased BMP pathway activity in pirfenidone treated cells. (A) BMP [(Bre)2-luc] pathway activity 
was analyzed using a promoter reporter assay. Promoter activities in pirfenidone (PFD) treated cells are shown 
relative to the level in each control (JL-1 or H2052), which was set to 1. The error bars represent SD (n = 3). 
*p < 0.05. (B) Expression of ID1 and GREM1 genes in pirfenidone (PFD) treated JL-1 and H2052 cells. The 
results are expressed relative to each control, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. 
(C) TGF-β [(CAGA)12-luc] pathway activity was analyzed in H2052 cells using a promoter reporter assay. 
Promoter activities in pirfenidone (PFD, 750 μg/ml) and/or TGF-β1 (0.5 ng/ml) treated cells are shown relative 
to the level in control, which was set to 1. (D) Pirfenidone (PFD, 750 μg/ml) and TGF-β1 (0.5 ng/ml) treated 
JL-1 and H2052 cell lysates were analyzed by Western blotting using antibodies specific to P-Smad2 and Smad2. 
The molecular weight markers (kDa) are shown on the left. The western blots were derived under the same 
experimental conditions from the same cell lysate of each treatment group (JL-1 and H2052). (E) Expression 
of TGFB1 gene in pirfenidone (PFD) treated JL-1 and H2052 cells. The results are expressed relative to each 
control, which was set to 1. The error bars represent SD (n = 3).
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FBLN1, LUM, VCAN) as well as matrix modifying proteolytic enzymes (e.g. MMP2, MMP3, ADAMTS4, Fig. 7E). 
Consistent with in vitro results pirfenidone also reduced GREM1 expression and induced BMP pathway target 
gene ID3 expression in vivo (Fig. 7F). In addition, TGFB3 and INHBA expression was decreased. We have pre-
viously shown high expression of FBN1 and FBN2 as well as MMP2 in association with high GREM1 expres-
sion in JP5 cells as well as in other mesothelioma cells11,12. Quantitative RT-PCR analyses confirmed that MMP2 
expression was significantly decreased in pirfenidone treated tumors (Fig. 7G). In addition, FBN1 showed a trend 
(p = 0.073) towards decreased expression. GREM1 levels were low and not reliably detectable by RT-PCR. We and 
others have shown that many of the differentially expressed genes identified by RNA sequencing are linked to a 
mesenchymal and chemoresistant phenotype in mesothelioma suggesting that pirfenidone treatment can alter 
the fibrotic tumor microenvironment.
Discussion
Mesothelioma is a cancer characterized by aggressive growth and local invasion. Mesothelioma originates from 
serosal mesothelial cells, which are mesodermal derived cells displaying both epithelial and mesenchymal char-
acteristics22. Mesothelioma cells often acquire a mesenchymal, migratory and chemoresistant phenotype12,23. The 
cells are embedded in a fibrotic, matrix rich microenvironment, which further favors resistance to chemotherapy. 
Growth factor activities such as BMP and TGF-β signaling pathways have been shown to regulate mesothelioma 
microenvironment and invasive growth1,12. TGF-β/activin pathways are increased in mesothelioma tumor tissue 
as well as in primary mesothelioma cells10,11. Activin-A was recently identified as a novel prognostic biomarker in 
epithelioid type mesothelioma24. We have shown that upregulation of gremlin-1 and modulation of BMP pathway 
activity is linked to invasion and vascularization in experimental mesothelioma xenograft tumors11. The TGF-β/
Figure 4. Pirfenidone reduces ERK activation. (A) JL-1 and H2052 cell lysates from control and pirfenidone 
(PFD, 500 µg/ml, 4 hours) treated cells were analyzed using a commercial phospho-protein array. Quantification 
of alterations in the amounts of phospho-proteins (n = 2) is shown. (B) JL-1 and H2052 cell lysates from 
pirfenidone (PFD, 500 µg/ml, 4 hours) treated cells were analyzed by P-MAPK ELISA. The results are expressed 
relative to each control, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (C) H2052 cell 
lysates from pirfenidone (PFD, 500 µg/ml) and/or TGF-β1 (0.5 ng/ml) treated (4 hours) cells were analyzed by 
P-ERK1/2 ELISA. The results are expressed relative to control, which was set to 1. The error bars represent SD 
(n = 3). *p < 0.05. (D) Pirfenidone (PFD) treated H2052 cell lysates were analyzed by Western blotting using 
antibodies specific to P-ERK1/2, ERK1/2 or tubulin. The molecular weight markers (kDa) are shown on the 
left. The western blots were derived under the same experimental conditions from the same cell lysate. (E) 
Quantification of band intensities. P-ERK/ERK levels were calculated and normalized using the tubulin loading 
control. The results are expressed relative to control, which was set to 1. The error bars represent SD (n = 3). 
*p < 0.05.
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BMP signaling balance is aberrantly regulated in mesothelioma similar to what we have observed in idiopathic 
pulmonary fibrosis (IPF), which is also characterized by connective tissue accumulation and migratory mesen-
chymal cell phenotypes14,15.
Figure 5. CREB and AKT pathway regulation by pirfenidone. (A) JL-1 cell lysates from pirfenidone (PFD, 
4 hours) or forskolin (FSK, 10 µM, positive control) treated cells were analyzed by CREB ELISA. P-CREB/CREB 
results are expressed relative to control, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (B) 
Cell lysates from pirfenidone (PFD, 750 µg/ml) and/or TGF-β1 (0.5 ng/ml) treated (4 hours) cells were analyzed 
by Western blotting using antibodies specific to P-AKT, AKT or tubulin. The molecular weight markers (kDa) 
are shown on the right. (C,D) Cell lysates from pirfenidone (PFD, 0–750 µg/ml) treated (1–4 hours) cells 
were analyzed by Western blotting using antibodies specific to P-CREB, AKT or tubulin. (E) Cell lysates from 
pirfenidone (PFD, 750 µg/ml), MG132 (10 µM) and/or TGF-β1 (0.5 ng/ml) treated (4 hours) cells were analyzed 
by Western blotting using antibodies specific to P-CREB, AKT or tubulin. (F) Quantification of AKT band 
intensities, which were normalized using the tubulin loading control. The results are expressed relative to each 
control (JL-1 or H2052), which was set to 1. The error bars represent SD (n = 3). *p < 0.05 when compared to 
the sample without any treatment. #p < 0.05. At least three independent experiments were performed for all 
quantifications. The western blots were derived under the same experimental conditions from the same cell 
lysate of each treatment group (B–E). The original full-length western blot images (D) and additional exposures 
(B) are shown in Supplementary figure 5.
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Repurposing of anti-fibrotic drugs to cancer treatment is not a novel idea and should be fully explored, espe-
cially to aggressive cancers with ECM rich microenvironment such as mesothelioma. Pirfenidone is a synthetic 
pyridone compound approved for the treatment of IPF first in Japan and later in Europe (2011) and US (2014). 
It has been shown to decrease fibroblast proliferation, ECM accumulation as well as to reduce inflammatory 
cell activity in the fibrotic lung25,26. In the present study, pirfenidone was found to significantly decrease mes-
othelioma cell proliferation. We also observed increased activity when combined with cisplatin but not with 
pemetrexed. This is in agreement with a recent study where pirfenidone and cisplatin in combination was shown 
to increase cell death in non-small cell lung cancer cells as well as in lung derived cancer-associated fibroblasts27. 
Mesothelioma cell migration/invasion through collagen matrix as well as invasive growth into 3D collagen were 
also found decreased by pirfenidone treatment. In agreement, a study by Surolia et al.28 indicated that in 3D 
spheroids cultured from IPF patient lung biopsy cells pirfenidone can reduce invasiveness. Pirfenidone was also 
able to reduce pancreatic stellate cell proliferation and migration/invasion through Matrigel matrix29. However, 
invasiveness through collagen matrix mimics better the microenvironment in the mesothelioma tumor tissue. 
Consistent with these events being regulated by TGF-β/BMP signaling activities, we observed increased BMP 
pathway activity and decreased gremlin-1 expression in pirfenidone treated mesothelioma cells.
The anti-fibrotic and anti-inflammatory mechanisms of action of pirfenidone are not fully characterized. It is 
mainly suggested to function through inhibition of TGF-β expression and/or TGF-β induced signal transduction 
pathways30,31. Pirfenidone modulates the properties of IPF fibroblasts and myofibroblasts by reducing prolifer-
ation and myofibroblastic appearance at the ultrastructural level32 and it was recently noted to reduce collagen 
fibril formation33. The hedgehog pathway activator GLI2 is also a suggested target of pirfenidone34. We observed 
downregulation of ERK activation by pirfenidone in TGF-β treated and non-treated mesothelioma cells. In rat 
proximal tubular epithelial cells pirfenidone was found to reduce ERK phosphorylation, but not p38 or Smad2 
phosphorylation, which fully agrees with our current observations35. They are also in agreement with our previ-
ous studies indicating that mesothelioma cell migration can be reduced with MEK inhibitors10.
Figure 6. p70S6K phosphorylation is decreased by pirfenidone (A). A schematic presentation of pirfenidone 
activity. (B) Cell lysates from pirfenidone (PFD, 750 µg/ml) treated (4 hours) cells were analyzed by Western 
blotting using antibodies specific to P-p70S6K/P-p85S6K, p70S6K/p85S6K or tubulin. (F) Quantification of 
P-p70S6K and p70S6K band intensities. P-p70S6K/p70S6K levels were calculated and the results are expressed 
relative to each control (JL-1 or H2052), which was set to 1. The error bars represent SD (n = 3–4). *p < 0.05. 
At least three independent experiments were performed for all quantifications. The western blots were derived 
under the same experimental conditions from the same cell lysate of each treatment group (JL-1 and H2052).
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Figure 7. Pirfenidone induces downregulation of the expression of ECM associated genes in vivo (A). JP5 
mesothelioma cells transduced to express a luciferase marker were injected subcutaneously as Matrigel plugs. 
Tumor growth was followed by luciferase signal measurements for 60 days. The error bars represent SEM (n = 8). 
(B) Images of luciferase signal detection of control and pirfenidone (PFD, 200 mg/kg/day) treated mice at day 60. 
(C) Subcutaneous tumors from control and pirfenidone (PFD) treated mice were stained with hematoxylin & 
eosin (HE), antibodies specific to human lamin A + C or the proliferation marker Ki67. Representative images are 
shown. (D) RNA sequencing was performed from Ctrl (n = 3) and pirfenidone (n = 4) treated tumors. Gene set 
enrichment analysis was performed using Reactome. Top hit pathways are shown. (E) A list of genes included in 
the “extracellular matrix organization” Reactome-pathway. Logarithmic fold change (logFC) and false discovery 
rate (FDR) for each gene are shown. (F) Differentially expressed TGF-β/BMP pathway genes. (G) Expression 
of FBN1 and MMP2 genes in the tumor tissue of control (Ctrl) and pirfenidone (PFD) treated mice (n = 7). 
Quantitative RT-PCR results are expressed relative to control tumor-1, which was set to 1.
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Interestingly, pirfenidone was able to significantly reduce AKT levels, likely through regulation of protein 
stability. In addition, pirfenidone reduced CREB phosphorylation in a time- and concentration-dependent man-
ner. CREB activation has been linked to gremlin-1 induced proangiogenic and proinfammatory activity as well 
as to mesothelioma cell survival36,37. Although in mesothelioma cells pirfenidone was not able to reduce canon-
ical Smad-mediated TGF-β signaling, it efficiently reduced TGF-β-mediated activation of ERK and AKT. Using 
inhibitors of MEK and AKT the effect of pirfenidone on mesothelioma cell proliferation was replicated. The 
results indicate that pirfenidone can target two major pathways, MAPK/ERK and PI3K/AKT, which are both 
activated in mesothelioma7. Our studies are in agreement with previous studies suggesting that pirfenidone can 
decrease EMT or myofibroblast differentiation by modulating MAPK or AKT pathways in other cell models25,38,39. 
Taken together, it is likely that multiple mechanism contribute to the effects of pirfenidone and that inhibition of 
non-canonical TGF-β-mediated signaling pathways plays a role in the anti-fibrotic and anti-cancer effects.
Oral administration of pirfenidone as a single agent did not reduce mesothelioma cell proliferation in a mouse 
xenograft model. Analyses of the effects of pirfenidone on metastasis formation was not possible in this model, 
since it would have taken a considerably longer follow-up time. The 200 mg/kg/day dose was selected based on 
previous mouse studies40. It is possible that a higher dose may have been effective; however, two studies using 
non-small cell lung cancer (NSCLC) xenograft mouse models suggested also that pirfenidone alone did not sig-
nificantly reduce tumor proliferation27,41. In both studies combining pirfenidone with a platin chemotherapy 
compound resulted in a significant decrease in tumor growth. Along these lines, studies proposed that in mam-
mary tumor models pirfenidone improves the anti-tumor efficacy of doxorubisin, likely through modulation of 
the tumor microenvironment e.g. by reducing collagen levels42,43. We hypothesize that pirfenidone in combina-
tion with chemotherapy is likely to have a similar therapeutic effect in mesothelioma. However, this remains to 
be demonstrated. We performed RNA sequencing of the tumors and found that pirfenidone downregulated the 
expression of several collagen genes as part of an extracellular matrix organization gene signature. Furthermore, 
the expression of GREM1 was downregulated by pirfenidone also in in vivo xenograft tumors consistent with 
cell culture observations. These results suggest that pirfenidone can modulate the tumor microenvironment by 
reducing fibrotic gene expression. This may reduce the ECM barrier, which hinders drug penetration into the 
tumor tissue. Consistent with this, in a mammary tumor model pirfenidone decreased interstitial fluid pressure 
and increased blood vessel functionality leading to better drug delivery43.
The kinase inhibitor nintedanib is an anti-fibrotic drug also used in the treatment of IPF and was recently 
tested in the treatment of mesothelioma in combination with pemetrexed/cisplatin chemotherapy regiment. A 
phase II study suggested that addition of nintedanib improved progression free survival in malignant pleural 
mesothelioma patients44. In our study, pirfenidone was shown to reduce two major upregulated pathways in 
mesothelioma and to target both tumor cells and the microenvironment, which makes it a candidate for similar 
clinical studies. Since mesothelioma is characterized with tumor suppressor gene mutations instead of activation 
of “druggable” oncogenes, targeting the upregulated signaling pathways presents a therapeutic approach. In addi-
tion, chemotherapy is often associated with fibrotic alterations in the tumor tissue, which further suggests that 
pirfenidone may present a novel anti-fibrosis and anti-cancer adjuvant therapy for mesothelioma.
Materials and Methods
Reagents and antibodies. Antibodies used for Western blotting were P-Smad2 (#3108), Smad2 (#5339), 
P-ERK1/2 (#9101), ERK1/2 (#9107), P-AKT (#9271), P-p70S6K (#108D2) and p70S6K (#2708) from Cell 
Signaling, P-CREB (RLP0075) and AKT (YT0178) from Immunoway (see Supplementary Fig. 1) and tubulin 
loading control (ab7291) from Abcam. Antibodies used for immunohistochemistry were anti-Ki67 (Abcam, 
ab16667) and anti-human laminA + C nuclear envelope marker (Abcam, ab108595), which was used to iden-
tify human tumor cells in mouse tissue. Pirfenidone, cisplatin, pemetrexed, the AKT inhibitor MK-2206 and 
the MEK inhibitor PD98059 were from Selleckchem. Pirfenidone concentrations ranging from 100–750 μg/ml 
(0.54–4.04 mM) were used in experiments. The proteasome inhibitor MG132 was from Sigma-Aldrich. TGF-β1 
was from R&D Systems.
Cell culture. Human mesothelioma cell line H2052 (CRL-5915) was from American Type Culture 
Collection (ATCC), human mesothelioma cell line JL-1 (ACC-596) from DSMZ-Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (Germany) and mouse mesothelioma cell line AB12 (CBA-0416) 
from Cell Bank Australia. JP5 mesothelioma cells were acquired from pleural effusion sample from a patient suf-
fering from malignant mesothelioma as described12. Cells were cultured in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10% (human cells) or 5% (mouse cells) heat-inactivated fetal bovine serum (FBS, Thermo 
Fisher Scientific), 1% L-glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml). Cells were incubated at 
37 °C in 5% CO2.
Proliferation assay. Cell proliferation/viability was assessed by WST-1 colorimetric assay (BioVision, 
Milpitas, CA). Briefly, cells were seeded into 96-well plates (5.000/well) and treated the next day with different 
concentrations of pirfenidone, cisplatin, pemetrexed or the inhibitors MK-2206 or PD98059 in medium contain-
ing 1% FBS. The metabolic activity of cells was measured after 48 hours according to the manufacturer’s instruc-
tions. At least three independent experiments were performed.
Cell Migration Assays. Transwell cell migration/invasion assays were performed as described previously11. 
The inserts (8 μm pores, Corning Costar) in 12-well plates were coated on the outer surface with collagen-I (45 μg/
ml, BD Bioscience) and the lower chamber was filled with serum-free medium. Cells (1–2 × 105) in serum-free 
medium were added to the upper chamber. Pirfenidone and other agents were added to the lower and upper 
chambers where indicated. After an 18-hour incubation the insert filters were fixed in 4% paraformaldehyde and 
www.nature.com/scientificreports/
1 1SCienTiFiC REPoRTs |  (2018) 8:10070  | DOI:10.1038/s41598-018-28297-x
stained with 0.5% crystal violet (in 20% methanol). Cells on the upper side of the membrane were scraped off, and 
migrated cells on the lower side were photographed using AxioVert 200 microscope (Carl Zeiss) and counted. At 
least three independent experiments were performed.
3D growth and invasion assay. The 3D collagen invasion assay was performed as described11. Briefly, 
cell spheroids were formed by culturing cells in 0.5% agarose coated 96-well round bottom plate. Spheroids were 
then picked up, mixed with type I collagen (Sigma) and dropped on the surface of a culture plate. After collagen 
polymerization, normal growth medium was added. Pirfenidone or water as a control was added to the collagen 
matrix and growth media where indicated. Growth and sprouting of cells from spheroids was monitored and 
photographed using AxioVert 200 microscope (Carl Zeiss). The spheroid surface area was determined using 
FijiImageJ 64 bit software as described11. Fold change was calculated by comparing the spheroid surface area to 
the surface area at time point zero, which was set to one. At least three independent experiments were performed.
TGF-β/BMP luciferase reporter assays. Cells were seeded into 96-well plates (5.000–10.000/well) prior 
to transfection. The cells were co-transfected with promoter constructs (CAGA)12-luc (Smad3 responsive) or 
(Bre)2-luc (Smad1/5 responsive), kindly provided by Dr. Peter ten Dijke (Leiden University Medical Center, the 
Netherlands), together with pRL-TK (Renilla luciferase control, Promega) plasmid using Fugene HD transfection 
reagent (Promega). After a three-day incubation, the cells were lysed and subjected to luciferase activity meas-
urement by Dual Luciferase Reporter Assay (Promoga) and FLUOstar Omega (BMG Labtech). The luciferase 
activities were normalized to constitutively expressed Renilla luciferase activities.
RNA isolation from cultured cells and quantitative RT-PCR. Total cellular RNA was isolated using 
RNeasy Mini kit (Qiagen) and reverse transcribed to cDNA using iScript cDNA synthesis Kit (Bio-Rad). The 
cDNAs were amplified using TaqMan Assays-on-Demand gene expression products (Applied Biosystems) and 
CFX96 Real-time PCR detection system (Bio-Rad). The relative gene expression differences were calculated with 
the comparative ΔΔCT method and the results are expressed as mRNA expression levels normalized to the levels 
of a gene with a constant expression (TBP, TATA-binding protein).
Western blotting analysis. Western blot analyses of whole-cell protein lysates (RIPA lysis buffer supple-
mented with protease and phosphatase inhibitors, Thermo Fisher Scientific) were performed as described12. 
Protein concentrations were assayed using a BCA protein assay Kit (Pierce). Equal amounts of protein were 
separated by SDS-PAGE using 4–20% gradient Tris-glycine gels (Bio-Rad) and transferred to nitrocellulose mem-
branes (Bio-Rad). After incubation with primary and secondary antibodies, the proteins were detected using 
Western Bright Quantum chemiluminescence detection system (Advansta). Scanning of gels was performed 
using Epson Perfection 4490 Photo Scanner, and quantification using Fiji ImageJ. In some cases, Odyssey imaging 
(Li-Cor Biosciences) was used and the relative band densities quantified with Image Studio Lite Ver 5.2 software 
(Li-Cor Biosciences).
Human phospho-kinase array. Control and pirfenidone treated cells were lysed and alterations in 
phospho-kinase levels were analyzed using a Proteome profiler array (ARY003b, R&D Systems) according to 
manufacturer’s instructions. Quantity One version 4.6 (BioRad, Hercules, CA) was used for quantification. The 
kinase array was performed twice.
ELISA assays. InstantOne ELISA kits (eBioscience) were used to detect CREB (total/phospho) or MAPK 
family activation (phosphorylated ERK1/2, p38 MAPK and JNK1/2) according to manufacturer’s instructions. 
Cells were treated with pirfenidone or other agents for 4 h in medium containing 1% FBS before lyses of cells and 
ELISA detection. The results are expressed relative to control. Three independent experiments were performed.
Subcutaneous mesothelioma xenografts. All experiments involving animals were approved by the 
Finnish National Animal Experiment Board (ESAVI/2083/04.10.07/2015) and carried out in accordance with 
University of Helsinki institutional guidelines, which fulfill the requirements defined in regulations of the Finnish 
Act on the Protection of Animals used for Scientific or Educational Purposes (497/2013) and were performed 
according to the 3 R. The experiments were carried out at the University of Helsinki Laboratory Animal Center. 
Female 6-week-old Balb/c nu/nu mice (Scanbur) were used. The mice were randomly divided into two groups 
upon arrival (n = 8). JP5 cells (1 × 106) expressing firefly luciferase were injected mixed with Matrigel matrix (BD 
Biosciences, final concentration 7 mg/ml) into the flank region of mice as previously described11. The procedures 
were performed under isoflurane anesthesia and the mice were observed until recovery. The treatment group 
received pirfenidone, which was started one day after cell injection (200 mg/kg in PBS, 200 μl by oral gavage) 
and continued daily until mice were sacrificed (60 days after cell injection). The control group received PBS only 
(200 μl by oral gavage). Successful injection of tumor cells as well as tumor growth was followed by biolumines-
cence imaging. D-Luciferin (Regis Technologies) in PBS was injected intraperitoneally and allowed to circulate 
for 10 min. Emitted photons were monitored with IVIS 100 whole animal imaging system (Perkin-Elmer). The 
weight of mice was monitored regularly throughout the experiment. Tumor tissue of sacrificed mice was collected 
in RNAlater solution (Life Technologies) or fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin.
Immunohistochemistry. Paraffin-embedded tissue samples were processed and stained using the Leica 
BOND-MAX fully automated staining system (Leica Bond Polymer Refine Detection-kit and Bond Epitope 
Retrieval Solution 1, 20 mins). The primary antibody incubation was 60 min. Negative control sections were 
incubated with rabbit isotype control (Invitrogen). The slides were scanned digitally (Pannoramic FLASH II, 
3DHistech) and analyzed using CaseViewer program and HistoQuant quantification module (3DHistech).
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RNA isolation from tumor xenografts, RNA sequencing and analysis. Total cellular RNA was 
isolated from tumor tissue using QIAzol and RNeasy Mini kit (Qiagen). RNA integrity was analyzed using 
TapeStation (Agilent) at the Biomedicum Functional Genomics Unit (HiLife, Helsinki). All the RIN values of the 
samples were >8.0. RNA libraries were constructed using TruSeq Stranded Total RNA with Ribo-Zero H/M/R 
(Illumina) and RNA sequencing (75 bp, SE) was performed using NextSeq. 500 (Illumina) at DNA Sequencing 
and Genomics Laboratory (Institute of Biotechnology, HiLife, Helsinki). Samples with total read alignment to 
more than 69% human genome (ranging between 69–86%; using STAR aligner to GRCh38.90) were analyzed in 
Chipster v3.12 using DESeq. 2 and edgeR for differential gene expression45,46. Principal component analyses per-
formed with DESeq. 2 indicated that 4/5 PFD-treated tumor samples clustered together, while 1/5 tumor sample 
was closer to the Ctrl-treated tumor sample cluster (n = 3). Two lists of differentially expressed coding genes (list-
1: PFD-treated samples n = 4, list-2: PFD-treated samples n = 5, Supplementary Table 1) were composed of genes 
identified by both algorithms, showing more than −0.6 or 0.6 fold change (FC) and FDR <0.01 (edgeR). All but 
one gene (17/18) in list-2 were present also in list-1 (127 genes), which was used for enriched pathway analysis 
using Reactome47,48. Verification of differential gene expression of selected genes was performed using human 
specific TaqMan Assays-on-Demand gene expression products (Applied Biosystems).
Statistical analyses. Comparisons were made using nonparametric tests with SPSS version 24 software 
(IBM). Two-group comparisons were made using Mann-Whitney U-test. P values below 0.05 (two-tailed) were 
considered statistically significant.
Data availability. The RNA sequencing data have been deposited in NCBI Gene Expression Omnibus 
(GEO) database49 and are accessible through GEO Series accession number GSE113803.
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